Serum estriol and placenta growth factor levels in pregnant women with subclinical hypothyroidism after thyroxine therapy
10.3760/cma.j.issn.1671-7368.2018.04.017
- VernacularTitle:亚临床甲状腺功能减退孕妇甲状腺替代治疗后血游离雌三醇及胎盘生长因子水平的检测
- Author:
Che XU
1
;
Feifei ZHAO
;
Fei XIE
Author Information
1. 首都医科大学附属复兴医院妇产科
- Keywords:
Hypothyroidism;
Hyroxine;
Estriol
- From:
Chinese Journal of General Practitioners
2018;17(4):313-316
- CountryChina
- Language:Chinese
-
Abstract:
Sixty four pregnancy women with mildly raised TSH level (2.5-4.5 mU/L) in the 1st trimester were divided into two groups:only the thyroid function was monitored in study Ⅰ group (n =32),while levothyroxine therapy was given in study Ⅱ group (n =32);45 normal pregnant women with TSH level ＜2.5 mU/L served as control group.Serum unconjugated estriol(uE3) and placenta growth factor (PlGF) levels in 3rd trimester were measured in all subjects.The incidence of adverse events in control group,study groups Ⅰ and Ⅱ were 22.2％,40.6％ and 31.3％,respectively (P ＞0.05).The serum levels of uE3 (7.34 μg/L) and PlGF (76.3 ng/L) were elevated in study group Ⅱ;and the uE3 level was close to that in the control group (6.61 μg/L),while PlGF level was lower than that in the control group (169.1 ng/L).When TPO antibody was positive,the uE3 level in the study group Ⅰ (logarithmic value 0.37 ±0.31) was lower than those in other two groups (logarithmic value 0.81 ± 0.37,0.56 ± 0.27),while there was no significant difference in PlGF levels among three groups.The results suggest that levothyroxine may improve placental function to some extent and TPO antibody might be one of the regulators in the expression of uE3.
